drugset
drugset / Trial / NCT03916679

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

NCT03916679 ↗

Phase 1/2 Unknown 20 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory epithelial ovarian cancer.

Timeline

Start
2019-04-20
Primary completion
2022-04-20
Completion
2023-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-MESO CAR-T cells Cell therapy — —

Indications

ovarian cancer